Cencora ( COR ) hasn’t received much coverage since early August, despite its growing relevance and strong fundamentals. The company remains largely overlooked by investors, yet I view it as one of the most attractive names in theHi there! I’m Narek, and I’ve been in the investment world for over six years. I started out as an equity analyst at European banks, digging into reports and learning how to spot value in the markets. I’ve worked across sectors — from telecom to industry — and found that behind eve ...

Cencora is set to invest $1bn by 2030 for expanding its US pharmaceutical distribution network, adding resilience and capacity to support customer needs across the country. This includes opening a second national distribution centre in Harrison, Ohio and expanding facilities in California and Alabama. The centre will span 530,000ft² and become operational by spring 2027. It aims to boost both throughput and storage capacity, incorporating advanced automation technologies, including autonomous mobile rob ...

Core Insights - Cencora, Inc. reported strong fourth-quarter fiscal 2025 results, with adjusted EPS of $3.84, exceeding estimates by 2.7% and showing a 15% year-over-year improvement [2][9] - The company achieved total revenues of $83.73 billion for the quarter, a 5.9% increase year-over-year, and also surpassed consensus estimates [4][9] - For the full fiscal year 2025, adjusted EPS was $16.00, reflecting a 16.3% increase from the previous year, while total revenues reached $321.33 billion, up 9.3% year-over-year [3][4] Revenue Details - Total revenues for the fourth quarter were $83.73 billion, up 5.9% year-over-year, beating the Zacks Consensus Estimate by 0.7% [4][9] - For fiscal 2025, total revenues were reported at $321.33 billion, marking a 9.3% increase year-over-year [4] Segmental Analysis - U.S. Healthcare Solutions segment revenues reached $75.8 billion, up 5.7% year-over-year, driven by increased sales of GLP-1 drugs and specialty products [5] - International Healthcare Solutions segment revenues amounted to $7.9 billion, reflecting a 7.6% year-over-year increase, with a 5.7% rise at constant currency [6] Margin Analysis - Adjusted gross profit was $2.9 billion, an 18.4% increase year-over-year, with an adjusted gross margin of 3.55%, up 36 basis points [8] - Adjusted operating income was $1.1 billion, up 20.6% year-over-year, with an adjusted operating margin of 3.47%, expanding 37 basis points from the previous year [8] Financial Update - The company ended the fiscal fourth quarter with cash and cash equivalents of $4.36 billion, significantly up from $2.23 billion in the previous quarter [10] - Cumulative net cash used in operating activities was $4.98 billion, compared to $618.1 million a year ago [10] Dividend Update - Cencora's board declared a quarterly dividend of 60 cents per share, payable on December 1, 2025, to shareholders of record by November 14, 2025 [11] FY26 Guidance Issued - The company provided guidance for fiscal 2026, estimating adjusted EPS in the range of $17.45-$17.75, with total revenues projected to grow by 5-7% [12][13] - U.S. Healthcare Solutions segment sales are expected to grow by 5-7%, while International Healthcare Solutions revenues are projected to rise by 6-8% [12][13] Overall Performance - Cencora's performance in the fourth quarter was strong, with earnings and revenues exceeding estimates, and the EPS guidance for fiscal 2026 was also above expectations [14] - The company has seen a 53.3% increase in shares year-to-date, outperforming the industry growth of 2.8% [14]

Cencora (NYSE:COR) Q4 2025 Earnings Call November 05, 2025 08:30 AM ET Company ParticipantsBob Mauch - CEOBennett Murphy - SVP of Investor RelationsJim Cleary - EVP and CFOConference Call ParticipantsSteven Valiquette - AnalystKevin Caliendo - AnalystCharles Rhyee - AnalystAllen Lutz - AnalystDaniel Grosslight - AnalystEric Percher - AnalystErin Wright - AnalystGeorge Hill - AnalystMichael Cherny - AnalystLisa Gill - AnalystElizabeth Anderson - AnalystBennett MurphyGood morning, good afternoon, and thank yo ...

Cencora (NYSE:COR) Q4 2025 Earnings Call November 05, 2025 08:30 AM ET Company ParticipantsBob Mauch - CEOBennett Murphy - SVP of Investor RelationsJim Cleary - EVP and CFOConference Call ParticipantsSteven Valiquette - AnalystKevin Caliendo - AnalystCharles Rhyee - AnalystAllen Lutz - AnalystDaniel Grosslight - AnalystEric Percher - AnalystErin Wright - AnalystGeorge Hill - AnalystMichael Cherny - AnalystLisa Gill - AnalystElizabeth Anderson - AnalystBennett MurphyGood morning, good afternoon, and thank yo ...

Cencora (NYSE:COR) Q4 2025 Earnings Call November 05, 2025 08:30 AM ET Speaker1Good morning, good afternoon, and thank you all for joining us for this conference call to discuss Sencora's fiscal 2025 fourth quarter and full year results. I am Bennett Murphy, Senior Vice President, Investor Relations and Enterprise Productivity. Joining me today are Bob Mauch, President and CEO, and Jim Cleary, Executive Vice President and CFO. On today's call, we will be discussing non-GAAP financial measures. Reconciliatio ...

Cencora (COR) came out with quarterly earnings of $3.84 per share, beating the Zacks Consensus Estimate of $3.79 per share. This compares to earnings of $3.34 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +1.32%. A quarter ago, it was expected that this prescription drug distributor would post earnings of $3.78 per share when it actually produced earnings of $4, delivering a surprise of +5.82%.Over the last four quarters, th ...

Cencora, Inc. Fourth Quarter Fiscal 2025 Earnings Call Cautionary Note Regarding Forward Looking Statements Certain of the statements contained in this presentation are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Securities Exchange Act"). Words such as "aim," "anticipate," "believe," "can," "continue," "could," "estimate," "expect," "intend," "may," "might," "on track," "op ...

Core Insights - Cencora plans to invest over $1 billion through 2030 to expand its U.S. distribution network, forecasting adjusted profit for next year above Wall Street expectations [1][3] Investment Plans - The company will build a second national distribution center in Harrison, Ohio, and expand sites in California and Alabama [1][2] - The Ohio hub will be 530,000 square feet and is expected to be operational by spring 2027, featuring advanced automation [2] - A new 430,000-square-foot distribution center in Fontana, California, will nearly double the size of the current site and is targeted to open by fall 2026 [3] Financial Performance - Cencora expects adjusted profit per share for 2026 to be between $17.45 and $17.75, slightly above analysts' expectations of $17.5 [3] - The company's U.S. Healthcare Solutions unit reported a 5.7% increase in sales to $75.79 billion for the quarter ended September 30, driven by strong prescription volumes of GLP-1 class drugs and specialty medicines [4] - Cencora reported fourth-quarter profit of $3.84 per share, exceeding analysts' estimates of $3.79 per share, with total sales of $83.73 billion, above the expected $83.46 billion [5]

Group 1 - The company will open two new distribution centers to meet the increasing demand for GLP-1s and other refrigerated medications [1] - A third distribution center will be expanded to further accommodate the surge in demand [1]